Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DWP14012 for Maintenance Therapy in Healed Erosive Esophagitis
NCT07746518Phase 3Not yet recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Aug 2029
01
Overview
Phase 3, randomised, double-blind trial of fexuprazan in erosive esophagitis (EE) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoint: Proportion of subjects who maintain endoscopic remission as assessed by an independent central reader at 24 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
fexuprazan
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on NCT07746518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07746518.